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The generation of excess reactive oxygen species (ROS) in mitochondria is responsible for much of the
oxidative stress associated with ageing (aging), and mitochondrial dysfunction is part of the pathology of
neurodegeneration and type 2 diabetes. Lipophilic pyridinium ions are known to accumulate in mito-
chondria and this paper describes a general route for the preparation of nitrone-containing N-arylpyr-
idinium salts having a range of lipophilicities, as potential therapeutic antioxidants. The compatibility of
nitrones with the Zincke reaction is the key to their synthesis. Their trapping of carbon-centred radicals
and the EPR spectra of the resulting nitroxides are reported.
 2009 Elsevier Ltd. Open access under CC BY license. 1. Introduction
The reactive oxygen species (ROS) generated within the mito-
chondria are ultimately responsible for much of the oxidative
damage that leads to the neurodegeneration associated with age-
ing.1 ROS produced by dysfunctional mitochondria also contribute
to increased risk of cardiovascular disease in people showing in-
sulin resistance through type 2 diabetes, which is also associated
with ageing.2 The life-expectancy of people is rising and the birth
rate is low in most developed countries and this is leading to an
ageing population so there is great interest in ensuring that people
have a healthy old age. Nitrones have shown potential for the
prevention and treatment of age-related diseases.3 One possible
mechanism for their action is the scavenging of the free radicals
that lead to oxidative damage. Nitrones 1 react with these highly
reactive oxygen-centred and carbon-centred radicals (Y) to give
nitroxides 2 that are more stable and longer lived (Scheme 1).4 The
nitroxides 2 can be detected by EPR spectroscopy and the hyperﬁne
splittings observed can often be used to identify the radical that led
to their formation. Thus, nitrones can be used as so-called spinR1 N
R2
O
Y
+
itrones.
: þ44 141 3304888.
).
 license. traps for the study of radical processes in biological samples. Cyclic
spin traps give observable nitroxides from both oxygen-centred
and carbon-centred radicals. Acyclic spin traps such asN-tert-butyl-
a-phenylnitrone, PBN (1 R1¼Ph, R2¼tBu), and N-tert-butyl-a-(N-
oxypyrid-4-yl)nitrone, POBN (1 R1¼N-oxypyrid-4-yl, R2¼tBu), give
long-lived adducts from carbon-centred radicals, and though the
adducts of hydroxy and hydroperoxy radicals fragment rapidly,
such traps are widely used with EPR spectroscopy5,6 and continue
to be developed for this purpose.7 Since acyclic nitrones have
shown promise for the treatment of age-related diseases,3 they are
also used as chemical interventions to study biological processes,
and new acyclic nitrones continue to be developed as potential
therapeutics.8 Stability to fragmentationwould not be important to
antioxidant activity if the overall pathway takes a reactive radical to
benign products.
A few nitrone spin traps 3–5 have been designed to accumulate
in mitochondria to scavenge and/or detect radicals generated there
(Fig. 1).9 All bear the lipophilic alkyltriphenylphosphonium (TPP)
cation, which has been pioneered as a targeting group for antiox-
idants by the groups of Murphy and Smith working in collabora-
tion.10 TPP cations easily permeate biological membranes and
accumulate up to a thousand-fold in the mitochondrial matrix due
to the large mitochondrial membrane potential across the inner
mitochondrial membrane set up by the electron transport chain.
Although the TPP-group is effective and relatively non-toxic, it is
not the only lipophilic cation that could act as a targeting group.We
considered the pyridinium ion as a lower-molecular-weight alter-
native, and here report the synthesis of PBN-analogues that in-
corporate this group.
There is precedent for the use of pyridinium ions in drug can-
didates to improve water solubility,11 but more importantly for us,
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Figure 3. Pyridinium salts used as spin traps.
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L. Robertson, R.C. Hartley / Tetrahedron 65 (2009) 5284–5292 5285pyridinium ions bearing lipophilic groups have been shown to ac-
cumulate in mitochondria.12,13 These include the rhodacyanine dye
MKT-077 6,12 which has anticarcinoma activity, and a ceramide
derivative 7 that induces mitochondrial permeabilization (through
the action of the ceramide moiety) (Fig. 2).13
A few PBN-type nitrone spin traps derived from N-alkylpyr-
idinium salts have been reported, but their use in targeting mito-
chondria has not been suggested. Janzen’s team studied the
behaviour of 2-, 3- and 4-(N-methylpyridinium) N-tert-butyl
nitrones (2-MePyBN, 3-MePyBN and 4-MePyBN 8, Fig. 3).14 These
spin traps were water-soluble and stable for several days in aque-
ous solution and the spin adducts were marginally longer lived
than those of PBN and 4-PyOBN at a range of pHs.15 The water-
soluble16 4-MePyBn 8 has since been used to study the chemical
effects of ultrasound.17 The N-dodecyl derivative 9 was also pre-
pared and was found to be almost insoluble in water,14 and the
related lipophilic N-linoleyl derivative 10 was used by Hill and
Thornalley as a membrane-bound spin trap for studying the gen-
eration of phenyl radicals when erythrocytes were treated with
phenylhydrazine.18 Interestingly, the resulting spectrum was iso-
tropic, showing that the nitroxide producedwas not immobilised in
themembrane.19 Nitrones 11 and 12 inwhich the tert-butyl group is
replaced with a bulkier, more lipophilic substituent have also have
also been reported.14,20
Nitrones derived from pyridinium salts have also been used for
purposes other than spin trapping. Some N-methylpyridinium
nitrones have been tested for anticancer activity,21 and a nitronyl
nitroxide pyridinium salt has been prepared as a spin-labelled
version of the biological co-factor nicotinamide adenine di-
nucleotide (NADþ).22 Related pyridinium salts have been
investigated as new materials, for example, in studies of molecule-
based mangnetism, and nitronyl nitroxide radical units have beenN
S
N
S
O Et
N
Et
Cl
MKT-077 6
OH
HN
N
O Br
OH
7
Figure 2. Pyridinium salts that accumulate in mitochondria.combined with an N-methylpyridinium ion to allow the ionic
bonding necessary for molecular packing.23
We reasoned that nitrones derived from N-arylpyridinium salts
would have a greater hydrophobic surface in the region of the
cation than primary alkylpyridinium salts 8–12 and would be ex-
cellent candidates for mitochondria-targeted antioxidants. Placing
the electron-withdrawing nitrone on a different aromatic ring from
the pyridinium unit should reduce the propensity for biological
reduction of the pyridinium ion relative to nitrones 8–12.
We decided to prepare three nitrones 13–15 that have in-
creasing lipophilicity (Fig. 4). The key reaction in the synthesis of
these N-arylpyridinium salts is the Zincke reaction,24,25 which re-
quires a two-step procedure (Scheme 2). First a pyridine 16 isNO2
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Scheme 2. Preparation of pyridinium salts.
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dinitrophenyl)pyridinium chloride 18, and this is then reacted with
an aniline 19 to give a new N-arylpyridinium salt 20 and 2,4-dini-
troaniline 21. The mechanism of this second step, which is the
Zincke reaction, involves nucleophilic attack by the nitrogen atom
of the aniline at C-2 of the pyridinium ion, ring opening, E–Z
interconversions, ring closure, and elimination of the 2,4-dini-
troaniline 21. In order for the formation of the N-(2,4-dini-
trophenyl)pyridinium chloride 18 to proceed well, the pyridine
must be nucleophilic, but if it is too electron-rich the Zincke re-
actionwith the aniline 19 is impeded, particularly if the latter bears
electron-withdrawing groups. Thus, the sequence will work best if
R2 is electron-donating, but R1 must be neither too electron-
withdrawing for the ﬁrst step nor too electron-donating for the
second.
The ﬁrst target was nitrone 13, which corresponds to the cat-
ionic head group alone. 1-Chloro-2,4-dinitrobenzene 17 reacted
smoothly with pyridine to give pyridinium salt 22. Zincke reaction
with the electron-rich aniline 23 in methanol was straightfor-
ward, but the resulting benzylic alcohol 24 failed to oxidise to the
aldehyde 26 under a variety of conditions. The oxidations were
made difﬁcult by the poor solubility of the alcohol in organic
solvents other than methanol and DMSO together with the difﬁ-
culty of separating different pyridinium salts from each other and
the high water solubility of the pyridinium salts (adaptations of
oxidation procedures to accommodate the solubility of the pyr-
idinium salt 24 included using manganese dioxide,26 IBX (stabi-
lised),27 hydrogen peroxide and iron(III) bromide,28 Swern and
Parikh–Doering oxidation29). Conversion into the benzylic chlo-
ride 25 with neat thionyl chloride and heating with sodium bi-
carbonate in DMSO30 also failed to give the desired product 26
(Scheme 3).
Next, introduction of the aldehyde masked as an acetal was
attempted (Scheme 4). 3-Nitrobenzaldehyde 27was converted into
acetal 28. Hydrogenation to give aniline 29 was carried out using
platinum oxide to avoid the acidity associated with Pd–C. Aniline
29 underwent the Zincke reaction smoothly with the N-(2,4-dini-
trophenyl)pyridinium salt 22 to give the pyridinium salt 30 in high
yield. Unfortunately, removal of the acetal groups proved less
straightforward with the 5,5-dimethyl-1,3-dioxane 30 failing to
cleave in 6 M aqueous hydrochloric acid (conditions chosen for ease
of isolating the water-soluble pyridinium salt product). Fortunately,
at this stage an alternative route had been successful (Scheme 5). 3-
Nitrobenzaldehyde 31 was converted into the N-tert-butylnitroneNO2
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Scheme 3. First approach.32. Selective hydrogenation of the nitro group then gave aniline 33,
which underwent the Zincke reaction with the N-(2,4-dini-
trophenyl)pyridinium salt 22 to give the desired water-soluble
nitrone 13. Some reduction of the nitrone was observed if the hy-
drogenation of the nitro compound was driven to completion and
the over-reduced side products were difﬁcult to remove and led to
paramagnetic contaminants in the ﬁnal product 13. Fortunately, the
starting nitro compound 32 was easily crystallised from a mixture
of nitrones 32 and 33 in ethanol–water when the hydrogenation
was stopped after consuming about half the starting material, and
this proved to be the best procedure.
With a route to the N-arylpyridinium head group in hand, we
set about modifying it to include a lipophilic tail. Initially 4-
methylpyridine 34 was converted into the 4-hexyl derivative 35
by lithiation–alkylation (Scheme 6). This readily formed an N-
(2,4-dinitrophenyl)pyridinium salt 36, but the latter did not react
with the aniline 33 bearing the electron-withdrawing nitrone
group. Clearly, the combination of a less electron-rich pyridine
and a more electron-rich aniline would be better. Therefore,
salicylaldehyde 37 was converted into 2-hexyloxybenzaldehyde
38 and dodecyloxybenzaldehyde 39 in high yield. Nitration gave
the corresponding nitro compounds 40 and 41 in modest yield
after separation from other nitrated products. Conversion to
nitrones 42 and 43 proceeded smoothly and hydrogenation,
optimised through a change of catalyst, gave anilines 44 and 45,
respectively. Although aniline 44 was isolated as a 5:1 mixture
with nitro compound 42, this did not present a problem in theNO2
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Figure 5. EPR spectrum of nitroxide 46 g¼2.0069, AN¼14.70 G (t), AHb¼2.45 G (d).
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lines and the N-(2,4-dinitrophenyl)pyridinium salt 22 now gave
the desired nitrones 14 and 15 (Scheme 7).
As expected for acyclic nitrone spin traps,4 trapping of oxygen-
centred radicals did not give stable nitroxides. On the other hand,
when the nitrones 13–15 were reacted with methyl radicals
generated from the reaction between DMSO and hydroxyl radicals
produced under Fenton conditions from hydrogen peroxide and
iron(II) sulfate (Scheme 8),4 EPR spectra were obtained that were
consistent with nitroxides 46–48 (Figs. 5–7). The high ﬁeld lines
are broadened due to mI-dependent linewidth effects and in-
complete averaging of the anisotropic components caused by re-
stricted tumbling of the spin adducts. Interestingly, the middle
doublet shows the greatest peak height for nitroxides 47 and 48,
which contain the long aliphatic tails, whereas, for nitroxide 46,
the lowest ﬁeld doublet is tallest. A weak background signal was
observed when samples of nitrone 13 were dissolved in DMSO–
water (Fig. 8), presumably due to nitroxide 49 (Fig. 9), which
would result from some reduction of the nitrone moiety of aniline
33 to a hydroxylamine during the hydrogenation of nitro com-
pound 32, followed by air-oxidation to the nitroxide. Nitrone 13OHC
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Scheme 7.produced under the optimised procedure was estimated to con-
tain about 2% of this impurity by integration of the signal at
d 1.42 ppm in the 1H NMR spectrum, presumed to result from its
tert-butyl group. The EPR signal for nitroxide 49 is visible in the
EPR spectrum of nitroxide 46 (Fig. 5) because EPR spectroscopy is
extremely sensitive and because the nitrone is used in excess
(2.5 equiv with respect to the hydrogen peroxide) so that while
the nitroxide 49 is already present, not all the nitrone 13 is con-
verted into nitroxide 46.Figure 6. EPR spectrum of nitroxide 47 g¼2.0057, AN¼14.83 G (t), AHb¼2.70 G (d).
Figure 7. EPR spectrum of nitroxide 48 g¼2.0057, AN¼14.90 G (t), AHb¼2.75 G (d).
N Cl
N
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Figure 9. Proposed nitroxide contaminant.
L. Robertson, R.C. Hartley / Tetrahedron 65 (2009) 5284–52925288In conclusion, we have reported a new type of spin trap that
bears an N-arylpyridinium ion, which should cause the more li-
pophilic members of the family 14 and 15 to accumulate in the
matrix of mitochondria to act as antioxidants there. The nitrones 14
and 15 react with methyl radicals to give nitroxides 47 and 48 that
give strong EPR signals, so they could potentially be used to detect
carbon-centred radicals within mitochondria. The synthesis dem-
onstrates the selective reduction of nitro groups in the presence of
nitrones, the compatibility of nitrones with the Zincke reaction
conditions, and illustrates the ﬁne balance that has to be struck
with regard to electron-donating and electron-withdrawing groups
in this reaction.2. Experimental
2.1. Synthesis
All reactions under an inert atmosphere were carried out using
oven dried or ﬂame dried glassware. Solutions were added via sy-
ringe. Diethyl ether, tetrahydrofuran, dichloromethane and toluene
were dried where necessary using a solvent drying system, Pure-
solv, in which solvent is pushed from its storage container underFigure 8. EPR spectrum of nitroxide 49 g¼2.0056, AN¼16.32 G (t), AHb¼10.35 G (t).low nitrogen pressure through two stainless steel columns con-
taining activated alumina and copper. Methanol was dried by dis-
tillation from magnesium and iodine, and then stored over 3 Å
molecular sieves. Reagents were obtained from commercial sup-
pliers and used without further puriﬁcation unless otherwise
stated. 1H and 13C NMR spectra were obtained on a Bruker DPX/400
spectrometer operating at 400 and 100 MHz, respectively. All
coupling constants are measured in hertz. DEPT was used to assign
the signals in the 13C NMR spectra as C, CH, CH2 or CH3. Mass
spectra (MS) were recorded on a Jeol JMS700 (MStation) spec-
trometer. Infra-red (IR) spectra were obtained using attenuated
total reﬂectance (ATR) so that the IR spectrum of the compound
(solid or liquid) could be directly detected (thin layer) without any
sample preparation.
2.2. N-tert-Butyl-a-[3-(pyrid-10-yl)phenyl]nitrone chloride 13
N-tert-Butyl-a-(3-aminophenyl)nitrone 33 (80 mg, 0.44 mmol)
was added to a stirred solution of N-(20,40-dinitrophenyl)pyr-
idinium chloride 22 (42 mg, 0.15 mmol) in anhydrous methanol
(4 mL) under argon at rt. After 2 h the resulting red mixture was
heated to reﬂux for 18 h until the red colour disappeared. The
mixture was cooled, diluted with H2O and washed with EtOAc until
no further colour was removed from the aqueous layer. The aque-
ous portionwas concentrated in vacuo to give pyridinium salt 13 as
a brown oil (40 mg, 96%). dH (400 MHz, MeOD): 1.68 (9H, s, 3CH3),
7.87 (1H, t, J 8.0 Hz, H-5), 7.97 (1H, ddd, J 8.1, 2.4 and 0.9 Hz, H-6),
8.21 (1H, s, CH]N), 8.37 (2H, dd, J 7.9 and 6.9 Hz, H-30 and H-50),
8.49 (1H, dt, J 7.9 and 1.4 Hz, H-4), 8.87 (1H, tt, J 7.9 and 1.3 Hz, H-40),
9.16 (1H, dd, J 2.0 and 1.8 Hz, H-2), 9.35 (2H, dd, J 6.9 and 1.4 Hz, H-
20 and H-60). dC (100 MHz, MeOD): 28.37 (CH3), 73.17 (C), 125.14
(CH),127.13 (CH),129.67 (CH),131.72 (CH),132.00 (CH),133.42 (CH),
134.57 (C), 144.38 (C), 146.12 (CH), 148.18 (CH). LRMS (FABþ) 255
[Mþ (pyridinium cation), 100%]. HRMS: 255.1501, C16H19N2O re-
quires 255.1497. nmax (ATR) 3074 (CH), 2980 (CH), 2934 (CH), 1628
(Ar), 1583 (Ar), 1472 (Ar), 1190 (nitrone) cm1.
2.3. N-tert-Butyl-a-[2-hexyloxy-5-(pyrid-10-yl)phenyl]nitrone
chloride 14
a-(5-Amino-2-hexyloxyphenyl)-N-tert-butylnitrone 44 [556 mg
of a mixture (5:1 mole ratio) of nitrones 44 and 42, 1.56 mmol] was
added to a stirred solution of N-(20,40-dinitrophenyl)pyridinium
chloride 22 (180 mg, 0.64 mmol) in anhydrous methanol (14 mL)
under argon at rt. After 2 h the resulting red mixture was heated to
reﬂux for 18 h until the red colour disappeared. The mixture was
cooled, diluted with H2O and washed with DCM until no further
colour was removed from the aqueous layer. The aqueous portion
was concentrated in vacuo to give 14 as an orange oil (189 mg, 76%).
dH (400 MHz, MeOD): 0.93 (3H, t, J 6.8 Hz, CH3), 1.36–1.44 (4H, m,
2CH2),1.52–1.60 (11H, m, 3CH3 and CH2),1.87–1.94 (2H, m, CH2),
4.24 (2H, t, J 6.2 Hz, CH2), 7.40 (1H, d, J 9.0 Hz, H-3), 7.90 (1H, dd, J
9.0 and 3.0 Hz, H-4), 8.32 (1H, s, CH]N), 8.34 (2H, dd, J 7.9 and
6.8 Hz, H-30 and H-50), 8.76 (1H, tt, J 7.9 and 1.3 Hz, H-40), 9.23 (2H,
dd, J 6.9 and 1.3 Hz, H-20 and H-60), 9.62 (1H, d, J 3.0 Hz, H-6). dC
(100 MHz, MeOD): 14.54 (CH3), 23.86 (CH2), 27.11 (CH2), 28.49
L. Robertson, R.C. Hartley / Tetrahedron 65 (2009) 5284–5292 5289(CH3), 30.13 (CH2), 32.80 (CH2), 70.90 (CH2), 73.38 (C), 114.15 (CH),
122.28 (C), 124.92 (CH), 126.49 (CH), 128.91 (CH), 129.76 (CH),
136.89 (C), 146.03 (CH), 147.71 (CH), 160.45 (C). LRMS (FABþ) 355
[Mþ (pyridinium cation), 100%]. HRMS: 355.2389, C22H31O2N2 re-
quires 355.2386. nmax (ATR) 2924 (CH), 2855 (CH), 1626 (aromatic),
1479 (aromatic), 1462 (aromatic), 1271 (nitrone), 1230 (C–O
stretch) cm1.
2.4. N-tert-Butyl-a-[2-dodecyloxy-5-(pyrid-10-yl)phenyl]-
nitrone chloride 15
a-(5-Amino-2-dodecyloxyphenyl)-N-tert-butylnitrone45 (517 mg,
1.38 mmol) was added to a stirred solution of N-(20,40-dini-
trophenyl)pyridinium chloride 22 (156 mg, 0.55 mmol) in an-
hydrous methanol (12 mL) under argon at rt. After 2 h the
resulting red mixture was heated to reﬂux for 18 h until the red
colour disappeared. The mixture was cooled, diluted with H2O
and washed with DCM until no further colour was removed
from the aqueous layer. The aqueous portion was concentrated
in vacuo to give nitrone 15 as an orange oil (129 mg, 49%). dH
(400 MHz, MeOD): 0.94 (3H, t, J 6.7 Hz, CH3), 1.34–1.67 (27H, m,
3CH3þ9CH2), 1.93–2.00 (2H, m, CH2), 4.30 (2H, t, J 6.2 Hz,
CH2), 7.46 (1H, d, J 9.0 Hz, H-3), 7.95 (1H, dd, J 9.0 and 3.0 Hz,
H-4), 8.33 (2H, dd, J 7.8 and 6.8 Hz, H-30 and H-50), 8.34 (1H, s,
CH]N), 8.82 (1H, tt, J 7.8 and 1.3 Hz, H-40), 9.30 (2H, dd, J 6.9
and 1.3 Hz, H-20 and H-60), 9.69 (1H, d, J 3.0 Hz, H-6). dC
(100 MHz, MeOD): 14.48 (CH3), 23.74 (CH2), 27.31 (CH2), 28.39
(CH3), 30.06 (CH2), 30.45 (CH2), 30.47 (CH2), 30.71 (CH2), 30.76
(CH2), 30.79 (CH2), 33.79 (CH2), 70.73 (CH2), 73.22 (C), 113.97
(CH), 122.21 (C), 124.76 (CH), 126.17 (CH), 128.70 (CH), 129.61
(CH), 136.76 (C), 145.91 (CH), 147.56 (CH), 160.28 (C). LRMS
(FABþ) 439 [Mþ (pyridinium cation), 100%]. HRMS: 439.3322,
C28H43O2N2 requires 439.3325. nmax (ATR) 2920 (CH), 2850 (CH),
1626 (aromatic), 1481 (aromatic), 1468 (aromatic), 1271
(nitrone), 1238 (C–O stretch) cm1.
2.5. N-(20,40-Dinitrophenyl)pyridinium chloride 22
Pyridine (4.0 mL, 49 mmol) and 1-chloro-2,4-dinitrobenzene
(10.01 g, 49.4 mmol) were heated together at 95 C for 1 h. The
resulting yellow solid was triturated with acetone until no further
colour was removed, to give pyridinium salt 22 as an off-white solid
(12.6 g, 91%). Mp 193–195 C. dH (400 MHz, MeOD): 8.39 (1H, d, J
8.7 Hz, H-60), 8.47 (2H, dd, J 7.9 and 6.8 Hz, H-3 and H-5), 8.97 (1H,
dd, J 8.7 and 2.5 Hz, H-50), 9.02 (1H, tt, J 7.9 and 1.3 Hz, H-4), 9.31
(1H, d, J 2.5 Hz, H-30), 9.40 (2H, dd, J 6.9 and 1.3 Hz, H-2 and H-6). dC
(100 MHz, MeOD): 121.35 (CH), 128.01 (CH), 130.20 (CH), 132.01
(CH), 138.72 (C), 143.05 (C), 146.08 (CH), 148.79 (CH), 149.00 (C).
LRMS (FABþ) 246 [Mþ (pyridinium cation), 100%]. HRMS: 246.0514,
C11H8N3O4 requires 246.0515. nmax (KBr) 3117, 3057, 1610 (aro-
matic), 1542 (NO2), 1473 (aromatic), 1342 (NO2) cm
1. 1H NMR and
13C NMR data consistent with literature data obtained in
(CD3)2SO.
31
2.6. N-(30-Hydroxymethylphenyl)pyridinium chloride 24
3-Aminobenzyl alcohol 23 (2.74 g, 22.3 mmol) was added to
a stirred solution of N-(20,40-dinitrophenyl)pyridinium chloride
22 (2.50 g, 8.90 mmol) in anhydrous methanol (60 mL) under
argon at rt. After 24 h, the resulting red mixture was heated to
reﬂux for 48 h until the red colour disappeared. The mixture was
cooled, diluted with H2O and washed with EtOAc until no further
colour was removed from the aqueous layer. The aqueous layer
was concentrated in vacuo to give a brown solid that was
recrystallised from iPrOH–acetone to give pyridinium salt 24 as
brown cubes (1.08 g, 55%). Mp 107–109 C. dH (400 MHz, MeOD):4.83 (2H, s, CH2OH), 7.75–7.79 (3H, m, H-40, H-50 and H-60), 7.85
(1H, br s, H-20), 8.33 (2H, dd, J 7.8 and 6.8 Hz, H-3 and H-5), 8.84
(1H, tt, J 7.8 and 1.3 Hz, H-4), 9.30 (2H, dd, J 6.9 and 1.4 Hz, H-2
and H-6). dC (100 MHz, MeOD): 62.41 (CH2), 121.96 (CH), 122.54
(CH), 128.07 (CH), 129.14 (CH), 130.14 (CH), 143.08 (C), 144.59
(CH), 145.13 (C), 146.39 (CH). LRMS (FABþ) 186 [Mþ (pyridinium
cation), 100%]. HRMS: 186.0916, C12H12NO requires 186.0919.
nmax (ATR) 3295 (OH), 2916 (CH), 2851 (CH), 1614 (aromatic), 1471
(aromatic) cm1.
2.7. N-(30-Chloromethylphenyl)pyridinium chloride 25
A mixture of N-(30-hydroxymethylphenyl)pyridinium chloride
24 (300 mg, 1.61 mmol) and SOCl2 (3.0 mL, 40.6 mmol) was heated
at 95 C under argon for 18 h. The reaction was cooled and the
excess SOCl2 was quenched by slow addition of H2O. The reaction
mixture was washed with CHCl3 and the aqueous portion was
concentrated in vacuo to give pyridinium salt 25 as a brown oil
(310 mg, 96%). dH (400 MHz, MeOD): 4.88 (2H, s, CH2Cl), 7.79–7.89
(3H, m, H-40, H-50 and H-60), 8.01 (1H, s, H-20), 8.36 (2H, m, H-3 and
H-5), 8.86 (1H, t, J 7.7 Hz, H-4), 9.32 (2H, d, J 6.1 Hz, H-2 and H-6). dC
(100 MHz, MeOD): 45.49 (CH2), 125.42 (CH), 125.77 (CH), 129.66
(CH), 132.12 (CH), 132.85 (CH), 142.41 (CH), 144.53 (C), 146.12 (C),
148.10 (CH). LRMS (FABþ) 204 [Mþ (35Cl, pyridinium cation), 100%],
206 [Mþ (37Cl, pyridinium cation), 33%]. HRMS: 204.0579 and
206.0553. C12H11
35ClN requires 204.0580 and C12H11
37ClN requires
206.0553. nmax (ATR) 3032 (CH), 2958 (CH), 1627 (aromatic), 1473
(aromatic) cm1.
2.8. 5,5-Dimethyl-2-(30-nitrophenyl)-1,3-dioxane 28
3-Nitrobenzaldehyde 27 (1.00 g, 6.62 mmol), 2,2-dimethyl-1,3-
propanediol (1.41 g, 13.6 mmol) and p-toluenesulfonic acid (24 mg,
0.12 mmol) were dissolved in anhydrous toluene (23 mL). The re-
actionwas heated under argon in a Dean–Stark apparatus at 140 C
for 24 h. Upon completion, the mixture was cooled, washed with
NaHCO3 (3), H2O and brine. The organic extracts were combined,
dried (MgSO4), and concentrated in vacuo to give acetal 28 as
a yellow oil (1.50 g, 95%) that solidiﬁed on standing. Mp 46–48 C.
dH (400 MHz, CDCl3): 0.81 (3H, s, CH3), 1.27 (3H, s, CH3), 3.67 (2H, d,
J 10.6 Hz, CH2O–), 3.78 (2H, d, J 10.1 Hz, CH2O–), 5.45 (1H, s, CHO2),
7.53 (1H, t, J 8.0 Hz, H-50), 7.81–7.83 (1H, m, H-40), 8.18 (1H, ddd, J
1.0, 2.3 and 8.2 Hz, H-60), 8.37 (1H, t, J 1.9 Hz, H-20). dC (100 MHz,
CDCl3): 21.86 (CH3), 23.07 (CH3), 30.31 (C), 77.70 (CH2), 99.92 (CH),
121.62 (CH), 123.69 (CH), 129.30 (CH), 132.49 (CH), 140.61 (C),
148.23 (C). LRMS (CIþ) 238 [(MþH)þ, 78%], 79 (100). HRMS:
238.1078, C12H16NO4 requires (MþH)þ, 238.1079. nmax (ATR) 2955
(CH), 2870 (CH), 1529 (NO2), 1460 (aromatic), 1348 (NO2), 1082 (C–
O stretch) cm1. 1H NMR and mp not in agreement with
literature.32
2.9. 2-(30-Aminophenyl)-5,5-dimethyl-1,3-dioxane 29
5,5-Dimethyl-2-(30-nitro-phenyl)-[1,3]dioxane 28 (825 mg,
3.48 mmol) and platinum(IV) oxide (16 mg, 5 mol %) were dis-
solved in ethyl acetate (16.5 mL). The solution was ﬂushed with
hydrogen then placed under a hydrogen atmosphere and stirred at
rt for 20 h. The catalyst was removed by ﬁltration through cotton
wool and the solution was concentrated in vacuo to give amine 29
as an orange-brown solid (720 mg, 100%). dH (400 MHz, CDCl3) 0.78
(3H, s, CH3), 1.30 (3H, s, CH3), 3.58–3.64 (4H, m, NH2þCH2), 3.74–
3.77 (2H, m, CH2), 5.30 (1H, s, CHO2), 6.61 (1H, ddd, J 0.9, 2.4 and
7.9 Hz, H-60), 6.83 (1H, t, J 2.0 Hz, H-20), 6.86–6.89 (1H, m, H-40), 7.13
(1H, t, J 7.8 Hz, H-50). dC (100 MHz, MeOD): 21.84 (CH3), 23.06 (CH3),
30.19 (C), 77.58 (CH2), 101.78 (CH), 112.67 (CH), 115.61 (CH), 116.31
(CH), 129.18 (CH), 139.55 (C), 146.53 (C). LRMS (EIþ) 207 (Mþ, 90%),
L. Robertson, R.C. Hartley / Tetrahedron 65 (2009) 5284–52925290121 (100). HRMS: 207.1263, C12H17NO2 requires 207.1259. nmax
(ATR) 3381 (NH2), 3360 (NH2), 2957 (CH), 1620 (NH2 bend), 1462
(aromatic), 1385, 1094 (C–O stretch) cm1; mp 60–61 C.2.10. N-[30-(500,500-Dimethyl-100,300-dioxan-200-yl)phenyl]-
pyridinium chloride 30
N-2,4-Dinitrophenyl pyridinium chloride 22 (333 mg,
1.18 mmol) was dissolved in anhydrous methanol (12 mL) and
amine 29 (613 mg, 2.96 mmol) was added. The reaction was stirred
under argon at rt for 20 h and then heated at reﬂux for 3 h until the
red colour disappeared. The mixture was cooled, diluted with H2O
and washed with EtOAc until no further colour was removed from
the aqueous layer. The aqueous portion was concentrated in vacuo
to give pyridinium salt 30 as a yellow oil (326 mg, 90%). dH
(400 MHz, MeOD): 0.87 (3H, s, CH3), 1.30 (3H, s, CH3), 3.81 (4H, s,
2CH2), 5.65 (1H, s, CHO2), 7.80 (1H, t, J 7.6 Hz, H-50), 7.86 (1H, ddd,
J 8.0, 2.4 and 1.3 Hz, H-40 or H-60), 7.91 (1H, dt, J 7.6 and 1.5 Hz, H-40
or H-60), 7.98–8.00 (1H, m, H-20), 8.32 (2H, dd, J 7.9 and 6.9 Hz, H-3
and H-5), 8.83 (1H, tt, J 1.4 and 7.9 Hz, H-4), 9.29 (2H, dd, J 6.9 and
1.4 Hz, H-2 and H-6). dC (100 MHz, MeOD): 21.91 (CH3), 23.32 (CH3),
78.57 (CH2), 101.09 (CH), 123.45 (CH), 125.73 (CH), 129.53 (CH),
130.66 (CH), 131.58 (CH), 143.29 (C), 144.38 (C), 146.20 (CH), 147.97
(CH). LRMS (FABþ) 270 [Mþ (pyridinium cation), 100%]. HRMS:
270.1488, C17H20NO2 requires 270.1494. nmax (ATR) 3007 (CH), 2949
(CH), 2868 (CH), 1628 (aromatic), 1473 (aromatic) cm1.2.11. N-tert-Butyl-a-(3-nitrophenyl)nitrone 32
3-Nitrobenzaldehyde 31 (500 mg, 3.31 mmol), N-(tert-butyl)-
hydroxylammonium acetate (740 mg, 4.96 mmol) and sodium hy-
drogen carbonate (417 mg, 4.96 mmol) were dissolved in ethanol
(40 mL). The reaction was heated, with stirring, at 70 C for 48 h.
The reaction mixture was poured into H2O (120 mL) and left to
stand for 1 h. The bright yellow crystals that formed were ﬁltered
off to give nitrone 32 as yellow, feathery crystals (641 mg, 92%). Mp
102–103 C (lit.33 108–110 C). dH (400 MHz, CDCl3): 1.62 (9H, s,
3CH3), 7.55 (1H, t, J 8.1 Hz, H-5), 7.69 (1H, s, CH]N), 8.18 (1H, dd, J
8.1 and 1.7 Hz, H-4), 8.57 (1H, dt, J 8.0 and 1.48 Hz, H-6), 9.17 (1H, t, J
1.7 Hz, H-2). dC (100 MHz, CDCl3): 28.31 (CH3), 71.99 (C), 123.18
(CH), 124.29 (CH), 127.94 (CH), 129.46 (CH), 132.53 (C), 133.99 (CH),
148.18 (C). LRMS (EIþ) 222 (Mþ, 10%), 84 (30%), 57 (C4H9þ, 100%).
HRMS: 222.1003, C11H14N2O3 requires 222.1004. nmax (KBr) 2985
(CH), 2940 (CH), 1556 (aromatic), 1522 (NO2), 1415 (aromatic), 1366
(NO2), 1339 (nitrone) cm
1. 1H NMR data consistent with literature
data obtained in (CD3)2SO.
332.12. N-tert-Butyl-a-(3-aminophenyl)nitrone 33
N-tert-Butyl-a-(3-nitrophenyl)nitrone 32 (500 mg, 2.34 mmol)
and platinum(IV) oxide (11 mg, 5 mol %) were dissolved in ethyl
acetate (10 mL). The solution was ﬂushed with hydrogen then
placed under a hydrogen atmosphere and stirred at rt for 45 min.
The catalyst was removed by ﬁltration through Celite and the so-
lution was concentrated in vacuo to give a 1:1.4 mixture of the
product 33 and starting material 32. The starting material 32 was
removed by precipitation from EtOH–H2O (2) as a crystalline
solid. The supernatant was concentrated to give a 10:1 mixture of
nitrones 33 and 32 as a yellow oil (108 mg, 40%; 81% based on re-
covered SM). dH (400 MHz, CDCl3): 1.49 (9H, s, 3CH3), 3.73 (2H, br
s, NH2), 6.63 (1H, ddd, J 7.9, 2.4 and 0.9 Hz, H-4), 7.07 (1H, t, J 7.9 Hz,
H-5), 7.19 (1H, d, J 7.8 Hz, H-6), 7.37 (1H, s, CH]N), 8.00 (1H, t, J
1.9 Hz, H-2). Material was carried on to next stage with no further
puriﬁcation or analysis due to potential instability.2.13. 4-Hexylpyridine 35
LDA (3.6 mL of 2 M in THF–heptane–ethylbenzene, 7.2 mmol)
was added dropwise over 10 min to a stirred solution of 4-picoline
34 (0.5 mL, 5.34 mmol) in anhydrous THF (5 mL) under argon at
78 C. After stirring for a further 30 min at78 C, a solution of 1-
bromopentane (0.44 mL, 3.6 mmol) in anhydrous THF (5 mL) was
added dropwise over 5 min and the mixture allowed to warm to rt
and stirred for 20 h. Saturated aqueous NH4Cl solution (10 mL) and
H2O (10 mL) were added and themixture was extracted with EtOAc
(2). The combined organic extracts were with H2O, dried (MgSO4)
and concentrated in vacuo to give a yellow oil. The crude residue
was chromatographed on SiO2 using EtOAc–hexane (1:9) as the
eluent to give 4-hexylpyridine 35 as a yellow oil (579 mg, 100%).
Rf¼[EtOAc–hexane (3:7)]: 0.23. dH (400 MHz, CDCl3): 0.87 (3H, t, J
6.8 Hz, CH3), 1.23–1.34 (6H, m, 3CH3), 1.57–1.64 (2H, m, CH2), 2.58
(2H, t, J 7.6 Hz, CH2), 7.10 (2H, d, J 5.9 Hz, H-3 and H-5), 8.47 (2H, d, J
5.8 Hz, H-2 and H-6). dC (100 MHz, CDCl3): 14.17 (CH3), 22.65 (CH2),
28.95 (CH2), 30.37 (CH2), 31.70 (CH2), 35.37 (CH2), 124.08 (CH),
149.52 (CH), 152.12 (C). LRMS (EIþ) 163 (Mþ, 30%), 93
[MþCH3(CH2)2CH]CH2, 100]. HRMS: 163.1358, C11H17N requires
163.1361. nmax (ATR) 2955 (CH), 2928 (CH), 2857 (CH), 1603 (aro-
matic), 1415 (aromatic) cm1. 1H NMR data agree with literature.342.14. 4-Hexyl-N-(20,40-dinitrophenyl)pyridinium chloride 36
4-Hexylpyridine 35 (2.27 g, 13.9 mmol) and 1-chloro-2,4-di-
nitrobenzene (5.62 g, 27.8 mmol) were heated together at 95 C for
48 h. The reaction was cooled, dissolved in H2O and washed with
EtOAc until no further colour was removed from the aqueous layer.
The aqueous portionwas concentrated in vacuo to give 36 as a dark
brown oil (4.29 g, 84%). dH (400 MHz, MeOD): 1.02 (3H, t, J 7.0 Hz,
CH3), 1.44–1.60 (6H, m, 3CH2), 1.94–2.01 (2H, m, CH2), 3.24 (2H, t, J
7.6 Hz, CH2), 8.36 (2H, d, J 6.4 Hz, H-3 and H-5), 8.44 (1H, d, J 8.7 Hz,
H-60), 8.98 (1H, dd, J 8.6 and 2.3 Hz, H-50), 9.29 (1H, d, J 2.4 Hz, H-30),
9.31 (2H, d, J 6.5 Hz, H-2 and H-6). dC (100 MHz, MeOD): 14.46
(CH3), 23.53 (CH2), 29.92 (CH2), 30.79 (CH2), 32.59 (CH2), 37.24
(CH2), 124.08 (CH), 129.12 (CH), 131.20 (CH), 132.92 (CH), 139.96 (C),
144.56 (C), 146.11 (CH), 150.82 (C), 169.12 (C). LRMS (FABþ) 330 [Mþ
(pyridinium cation), 100%]. HRMS: 330.1452, C17H20O4N3 requires
330.1454. nmax (ATR) 2928 (CH), 2859 (CH), 1610 (aromatic), 1537
(NO2), 1462 (aromatic), 1342 (NO2) cm
1.2.15. 2-Hexyloxybenzaldehyde 38
1-Bromohexane (4.7 mL, 0.034 mol) was added to a solution of
salicylaldehyde (3.0 mL, 0.028 mol) and K2CO3 (4.647 g, 0.034 mol)
in DMF (40 mL). The reactionwas heated, with stirring, at 130 C for
20 h. The reaction was cooled, ﬁltered and diluted with H2O. The
mixture was extracted with EtOAc (3) and the combined organic
extracts were washed with 1 M KOH. The organic extracts were
dried (MgSO4) and concentrated in vacuo to give aldehyde 38 as
a yellow oil (5.768 g, 99%). dH (400 MHz, CDCl3): 0.86–0.89 (3H, m,
CH3), 1.27–1.33 (4H, m, 2CH2), 1.41–1.47 (2H, m, CH2), 1.76–1.83
(2H, m, CH2), 4.01 (2H, t, J 6.4 Hz, CH2), 6.93 (1H, d, J 8.4 Hz, H-3),
6.94 (1H, t, J 7.5 Hz, H-5), 7.47 (1H, ddd, J 8.5, 7.4 and 1.8 Hz, H-4),
7.78 (1H, dd, J 7.7 and 1.8 Hz, H-6), 10.48 (1H, s, CHO). dC (100 MHz,
CDCl3): 14.00 (CH3), 22.57 (CH2), 25.72 (CH2), 29.02 (CH2), 31.50
(CH2), 68.46 (CH2), 112.47 (CH), 120.38 (CH), 124.81 (C), 128.05 (CH),
135.92 (CH), 161.56 (C), 189.78 (CH). LRMS (EIþ) 206 (Mþ, 15%), 122
(30%), 85 (65%), 83 (100%). HRMS: 206.1309, C13H18O2 requires
206.1307. nmax (ATR) 2955 (CH), 2859 (CH), 1688 (C]O), 1599 (ar-
omatic), 1456 (aromatic), 1240 (C–O stretch) cm1. Literature re-
ports microanalysis only.35
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1-Iodododecane (8.38 mL, 0.034 mol) was added to a solution of
salicylaldehyde (3.0 mL, 0.028 mol) and K2CO3 (4.647 g, 0.034 mol)
in DMF (40 mL). The reactionwas heated, with stirring, at 130 C for
20 h. The reaction was cooled, ﬁltered and diluted with H2O. The
mixture was extracted with EtOAc (3) and the combined organic
extracts were washed with 1 M KOH. The organic extracts were
dried (MgSO4) and concentrated in vacuo to give aldehyde 39 as
a yellow solid, which melts upon handling (8.0295 g, 99%). dH
(400 MHz, CDCl3): 0.87 (3H, t, J 6.2 Hz, CH3), 1.22–1.35 (16H, m,
8CH2), 1.43–1.47 (2H, m, CH2), 1.79–1.86 (2H, m, CH2), 4.05 (2H, t, J
6.4 Hz, CH2), 6.94–6.99 (2H, m, H-4 and H-5), 7.48–7.52 (1H, m, H-
3), 7.81 (1H, d, J 7.6 Hz, H-6), 10.50 (1H, s, CHO). dC (100 MHz,
CDCl3): 14.19 (CH3), 22.77 (CH2), 26.13 (CH2), 29.16 (CH2), 29.43
(CH2), 29.54 (CH2), 29.64 (CH2), 29.67 (CH2), 29.71 (CH2), 29.73
(CH2), 31.99 (CH2), 68.57 (CH2), 112.54 (CH), 120.48 (CH), 124.94 (C),
128.20 (CH), 135.96 (CH), 161.64 (C), 189.90 (CH). LRMS (EIþ) 290
(Mþ, 60%), 122 (100). HRMS: 290.2244, C19H30O2 requires
290.2246. nmax (ATR) 2922 (CH), 2853 (CH), 1688 (C]O), 1599 (ar-
omatic), 1458 (aromatic), 1240 (C–O stretch) cm1.
2.17. 2-Hexyloxy-5-nitrobenzaldehyde 40
A mixture of fuming nitric acid (100%, d¼1.52, 7 mL) and con-
centrated sulfuric acid (18.1 M, 7 mL) was cooled, with stirring, to
10 C. 2-Hexyloxybenzaldehyde 38 (5.55 g, 269 mmol) was added
dropwise to the mixture. The reaction was allowed to warm to rt.
After 1 h the reaction was poured onto ice. The precipitate formed
was ﬁltered, washed with H2O and dissolved in Et2O. The ether
solution was washed with H2O, saturated aqueous NaHCO3 (3)
and again with H2O. The organic extracts were dried (MgSO4) and
concentrated in vacuo to give a yellow solid. This solid was
recrystallised three times from Et2O–hexane to give aldehyde 40 as
off-white needles (1.49 g, 22%). Mp 61–62 C (lit.36 66–70 C). dH
(400 MHz, CDCl3): 0.91 (3H, t, J 6.8 Hz, CH3), 1.35–1.38 (4H, m,
2CH2), 1.47–1.52 (2H, m, CH2), 1.87–1.94 (2H, m, CH2), 4.21 (2H, t, J
6.4 Hz, CH2), 7.10 (1H, d, J 9.2 Hz, H-3), 8.41 (1H, dd, J 9.2 and 2.8 Hz,
H-4), 8.69 (1H, d, J 2.8 Hz, H-6), 10.47 (1H, s, CHO). dC (100 MHz,
CDCl3): 14.11 (CH3), 22.65 (CH2), 25.71 (CH2), 28.90 (CH2), 31.52
(CH2), 70.00 (CH2), 113.00 (CH),124.64 (CH),124.66 (C), 130.78 (CH),
141.49 (C), 165.39 (C), 187.77 (CH). LRMS (EIþ) 251 (Mþ, 85%), 84
(65), 43 (100). HRMS: 251.1157, C13H17NO4 requires 251.1158. nmax
(ATR) 2951 (CH), 2911 (CH), 2843 (CH), 1688 (C]O), 1609 (aro-
matic), 1512 (NO2), 1427 (aromatic), 1339 (NO2), 1273 (C–O
stretch) cm1.
2.18. 2-Dodecyloxy-5-nitrobenzaldehyde 41
A solution of 2-dodecyloxybenzaldehyde 39 (3.79 g,13 mmol) in
concentrated sulfuric acid (3 mL) was cooled, with stirring, to
10 C. A mixture of 70% nitric acid (1.3 mL) and concentrated
sulfuric acid (18.1 M, 1.3 mL) was also cooled, with stirring, to
10 C. The acid mixture was added dropwise to the aldehyde so-
lution and the mixture stirred at rt for 15 min. The reaction mixture
was poured onto ice. The aqueous layers were extracted with EtOAc
(3). The combined organic extracts were washed with H2O (3),
dried (MgSO4) and concentrated in vacuo to give an orange oil.
Chromatography on SiO2 using 5% EtOAc–hexane (1:19) as the el-
uent gave 41 as a yellow oil (1.141 g, 34%). Rf¼0.40 [EtOAc–hexane
(1:4)]. dH (400 MHz, CDCl3): 0.83 (3H, t, J 6.5 Hz, CH3), 1.22–1.35
(16H, m, 8CH2), 1.44–1.51 (2H, m, CH2), 1.85–1.92 (2H, m, CH2),
4.20 (2H, t, J 6.5 Hz, CH2), 7.10 (1H, d, J 9.2 Hz, H-3), 8.36 (1H, dd, J
9.2 and 2.8 Hz, H-4), 8.60 (1H, d, J 2.8 Hz, H-6), 10.42 (1H, s, CHO). dC
(100 MHz, CDCl3): 14.14 (CH3), 22.72 (CH2), 25.94 (CH2), 28.86
(CH2), 29.30 (CH2), 29.38 (CH2), 29.54 (CH2), 29.59 (CH2), 29.66(CH2), 31.62 (CH2), 31.94 (CH2), 69.99 (CH2), 113.04 (CH), 124.31
(CH), 124.54 (C), 130.64 (CH), 141.32 (C), 165.35 (C), 187.58 (CH).
LRMS (EIþ) 335 (Mþ, 22%), 318 (45), 97 (49), 85 (70), 71 (88), 57
(C4H9
þ, 100). HRMS: 335.2096, C19H29NO4 requires 335.2097. nmax
(ATR) 2924 (CH), 2853 (CH), 1692 (C]O), 1609 (aromatic), 1589
(aromatic), 1522 (NO2), 1466 (aromatic), 1341 (NO2), 1271 (C–O
stretch) cm1.
2.19. N-tert-Butyl-a-(2-hexyloxy-5-nitrophenyl)nitrone 42
2-Hexyloxy-5-nitrobenzaldehyde 40 (490 mg, 1.95 mmol), N-
(tert-butyl)hydroxylammonium acetate (437 mg, 2.93 mmol) and
sodium hydrogen carbonate (246 mg, 2.93 mmol) were dissolved in
ethanol (20 mL). The reaction was heated, with stirring, at 70 C for
72 h. The reaction mixture was poured into H2O (100 mL) and left
to stand for 1 h. The resulting precipitate was ﬁltered and dissolved
in EtOAc. The solution was washed with H2O (2) and brine, dried
(MgSO4) and concentrated in vacuo to give a yellow solid. The solid
was recrystallised from Et2O–hexane to give nitrone 42 as yellow
cubes (610 mg, 97%). Mp 102–103 C. dH (400 MHz, CDCl3): 0.92
(3H, t, J 6.7 Hz, CH3), 1.34–1.39 (4H, m, 2CH2), 1.46–1.54 (2H, m,
CH2), 1.63 (9H, s, 3CH3), 1.85–1.92 (2H, m, CH2), 4.14 (2H, t, J
6.4 Hz, CH2), 6.95 (1H, d, J 9.2 Hz, H-3), 8.16 (1H, s, CH]N), 8.27 (1H,
dd, J 9.1 and 2.6 Hz, H-4), 10.24 (1H, d, J 2.6 Hz, H-6). dC (100 MHz,
CDCl3): 14.12 (CH3), 22.73 (CH2), 25.85 (CH2), 28.36 (CH3), 28.98
(CH2), 31.55 (CH2), 69.48 (CH2), 72.04 (C), 110.32 (CH), 120.54 (C),
123.33 (CH), 124.05 (CH), 126.87 (CH), 141.25 (C), 160.95 (C). LRMS
(EIþ) 322 (Mþ, 20%), 266 (MþC4H8, 70), 57 (C4H9þ, 100). HRMS:
322.1896, C17H26N2O4 requires 322.1893. nmax (ATR) 2951 (CH),
2982 (CH), 1609 (aromatic), 1580 (aromatic), 1516 (NO2), 1466 (ar-
omatic), 1343 (NO2), 1273 (nitrone), 1248 (C–O stretch) cm
1.
2.20. N-tert-Butyl-a-(2-dodecyloxy-5-nitrophenyl)nitrone 43
2-Dodecyloxy-5-nitrobenzaldehyde 41 (1.41 g, 4.40 mmol), N-
(tert-butyl)hydroxylammonium acetate (984 mg, 6.60 mmol) and
sodium hydrogen carbonate (554 mg, 6.60 mmol) were dissolved in
ethanol (40 mL). The reaction was heated, with stirring, at 70 C for
48 h. The reaction mixture cooled, diluted with H2O and extracted
with EtOAc (3). The combined organic extracts were washed with
H2O (2) and brine (1), dried (MgSO4) and concentrated in vacuo
to give nitrone 43 as a yellow solid (1.60 g, 90%). Mp 39–40 C. dH
(400 MHz, CDCl3): 0.88 (3H, t, J 6.4 Hz, CH3), 1.27–1.40 (16H, m,
8CH2), 1.47–1.52 (2H, m, CH2), 1.63 (9H, s, 3CH3), 1.85–1.92 (2H,
m, CH2), 4.13 (2H, t, J 6.4 Hz, CH2), 6.93 (1H, d, J 9.2 Hz, H-3), 8.09
(1H, s, CH]N), 8.24 (1H, dd, J 9.1 and 2.7 Hz, H-4), 10.28 (1H, d, J
2.7 Hz, H-6). dC (100 MHz, CDCl3): 14.25 (CH3), 22.81 (CH2), 26.18
(CH2), 28.39 (CH3), 29.03 (CH2), 29.40 (CH2), 29.46 (CH2), 29.68
(CH2), 29.73 (CH2), 29.75 (CH2), 29.77 (CH2), 32.03 (CH2), 69.45
(CH2), 72.01 (C), 110.27 (CH), 120.72 (C), 122.70 (CH), 123.92 (CH),
126.69 (CH), 141.28 (C), 160.87 (C). LRMS (EIþ) 406 (Mþ, 12%), 350
(70), 318 (65), 182 (73), 57 (C4H9
þ, 100). HRMS: 406.2829,
C23H38N2O4 requires 406.2832. nmax (ATR) 2955 (CH), 2920 (CH),
2851 (CH), 1607 (aromatic), 1518 (NO2), 1464 (aromatic), 1339
(NO2), 1271 (nitrone), 1244 (C–O stretch) cm
1.
2.21. a-(5-Amino-2-hexyloxyphenyl)-N-tert-butylnitrone 44
N-tert-Butyl-a-(2-hexyloxy-5-nitrophenyl)nitrone 42 (613 mg,
1.90 mmol) and palladium hydroxide (20% on carbon, 66 mg,
5 mol %) were dissolved in ethyl acetate (9.5 mL). The solution was
ﬂushed with hydrogen then placed under a hydrogen atmosphere
and stirred at rt for 30 min. The catalyst was removed by ﬁltration
through Celite and the solution was concentrated in vacuo to give
a 5:1 mixture of a-(5-amino-2-hexyloxyphenyl)-N-tert-butylni-
trone 44 and nitrone 42 as a yellow oil (556 mg, approx. 82% yield
L. Robertson, R.C. Hartley / Tetrahedron 65 (2009) 5284–52925292of nitrone 44). Data derived for nitrone 44: dH (400 MHz, CDCl3):
0.87 (3H, t, J 7.1 Hz, CH3), 1.29–1.34 (4H, m, 2CH2), 1.40–1.47 (2H,
m, CH2), 1.56 (9H, s, 3CH3), 1.70–1.77 (2H, m, CH2), 3.45 (2 h, br s,
NH2), 3.88 (2H, t, J 6.4 Hz, CH2), 6.64–6.69 (2H, m, H-5 and H-6),
8.01 (1H, s, CH]N), 8.78 (1H, d, J 2.6 Hz, H-2)]. Material was carried
on to next stage with no further puriﬁcation or analysis.
2.22. a-(5-Amino-2-dodecyloxyphenyl)-N-tert-butyl-
nitrone 45
N-tert-Butyl-a-(2-dodecyloxy-5-nitrophenyl)nitrone 43 (563 mg,
1.38 mmol) and palladium hydroxide (20% on carbon, 48 mg,
5 mol %) were dissolved in ethyl acetate (7.5 mL). The solution
was ﬂushed with hydrogen then placed under a hydrogen at-
mosphere and stirred at room temperature for 50 min. The
catalyst was removed by ﬁltration and the solution was con-
centrated in vacuo to give 45 as a brown solid (517 mg, 99%). dH
(400 MHz, CDCl3): 0.87 (3H, t, J 6.3 Hz, CH3), 1.21–1.34 (16H, m,
8CH2), 1.42–1.47 (2H, m, CH2), 1.59 (9H, s, 3CH3), 1.73–1.78
(2H, m, CH2), 3.40 (2H, br s, NH2), 3.91 (2H, t, J 6.4 Hz, CH2),
6.69–6.73 (2H, m, H-5 and H-6), 8.05 (1H, s, CH]N), 8.82 (1H,
d, J 2.3 Hz, H-2). The material was carried onto next stage with
no further puriﬁcation or analysis.
2.23. EPR spectroscopy
Iron(II) sulfate (100 mL of a 1 mM aqueous solution) and hy-
drogen peroxide (100 mL of a 1 mM aqueous solution) were added
to a solution of the nitrone 13,14 or 15 in DMSO (100 mL of a 2.5 mM
solution in the case of nitrone 13 and a 10 mM solution for nitrones
14 and 15). The solution [0.83 mMnitrone 13 or 3.33 mMnitrone 14
or 15, 0.33 mM hydrogen peroxide, 0.33 mM iron(II) sulfate in
water–DMSO (2:1)] was then immediately transferred to a quartz
ﬂat cell and placed in the EPR spectrometer for analysis. Spectra
were acquired on a Bruker e-scan bench-top EPR machine with
a permanent magnet and a magnetic sweep circuit (centre of
ﬁeld¼0.345 T, sweep width 25 mT) operating at a frequency of
9.8 GHz (X-band). Acquisition parameters: RG 3.99103, 2.76 mW,
MA 0.5 G. Hyperﬁne couplings were derived from simulations us-
ing WINEPR SimFonia.
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